BioStock: Idogen's study approved in Norway and Sweden

Idogen has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The... | April 19, 2022

Related Keywords

Norway ,Sweden ,Swedish ,Norwegian , ,Norwegian Medical ,Idogen Ab Publ Stock Exchange ,News ,Information ,Press Release ,Hydogen ,Gas ,Eceived ,The ,Rom ,Moth ,End ,O ,Nitiate ,Linical ,Hase ,Study ,Ith ,Fell ,Therapy ,Edo ,N ,Emophilia Idogen Se0014428561 ,